drugset / Trial / NCT02182076

Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

NCT02182076

Phase 1 Completed 15 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess pharmacokinetics and the extend of absorption of a single dose of BIBF 1120 soft gelatine capsule with food effect (BA) in healthy subjects respectively.

Timeline

Start
2005-10
Primary completion
2005-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 150 mg

Indications

No indication recorded.